Business

Here’s what our $132b biotech giant plans to do next

Australians became familiar with CSL through the pandemic, but as the company emerges from COVID, it has ambitious new plans to disrupt a variety of medical ailments.

Business / Companies

Brisbane Times – Business

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Business